Bernstein SocGen has revised its stock price target for BioMarin Pharmaceutical following an update on the company's guidance. This adjustment reflects changes in expectations regarding BioMarin's financial performance and market conditions. The firm has communicated its new target to investors, indicating a shift in outlook for the pharmaceutical company's future prospects.
Related Articles
Don't miss out on breaking stories and in-depth articles.